Pulmonary hypertension owing to lung disease and/or hypoxia Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

2 events

Jan 2025DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

United Therapeutics — NA

TrialRECRUITING

Apr 2000Flolan: FDA approved

treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Pulmonary hypertension owing to lung disease and/or hypoxia.
Check the disease page for updates →